Vyleesi and Testosterone Interaction: What Women Need to Know

What Is the Bremelanotide-Testosterone Interaction?

The combination of bremelanotide and testosterone does not involve a classic cytochrome P450 or P-glycoprotein drug-drug interaction. The concern is pharmacodynamic: both agents affect cardiovascular physiology, hematocrit, and lipid profiles in ways that can compound each other. Women taking testosterone for hypoactive sexual desire disorder (HSDD) or genitourinary syndrome of menopause (GSM) who then add bremelanotide face additive hemodynamic and hematologic risk, not enzymatic competition.

Understanding why requires a close look at how each drug works in the female body.

How Bremelanotide Works

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in June 2019 for premenopausal women with acquired, generalized HSDD. It activates melanocortin receptors MC1R, MC3R, MC4R, and MC5R in the central nervous system, increasing dopaminergic tone and dampening serotonin-mediated inhibition of desire. It is administered as a 1.75 mg subcutaneous injection approximately 45 minutes before anticipated sexual activity, no more than once every 24 hours and no more than eight times per month.

Bremelanotide transiently raises blood pressure. In the RECONNECT trial, which enrolled 1,247 premenopausal women, mean maximum systolic BP increased by approximately 6 mmHg and diastolic by approximately 3 mmHg, peaking around 4 hours post-dose and resolving by 12 hours. Because of this, the drug is contraindicated in women with uncontrolled hypertension or known cardiovascular disease.

How Testosterone Works in Women

Testosterone in women is prescribed off-label in the United States for HSDD and, increasingly, for energy and musculoskeletal concerns in perimenopause and menopause. Testosterone pellets, gels, and creams are the most commonly used formulations, though no testosterone product is FDA-approved specifically for women at this time. The Global Consensus Position Statement on the use of testosterone therapy for women, endorsed by multiple international societies including The Menopause Society, supports use for postmenopausal HSDD at doses that maintain serum testosterone in the physiologic premenopausal female range (free testosterone roughly 0.5 to 2.4 ng/dL by LC-MS/MS).

Even at female-appropriate doses, testosterone therapy carries known risks: erythrocytosis (elevated hematocrit), suppression of HDL cholesterol, and, at supraphysiologic doses, virilization. Pellet therapy is particularly associated with supraphysiologic testosterone levels and warrants closer monitoring.

The Pharmacodynamic Overlap: Where the Risks Compound

Neither bremelanotide nor testosterone is metabolized predominantly by CYP3A4, CYP2D6, or P-glycoprotein in ways that would cause classic pharmacokinetic interaction. The FDA label for bremelanotide notes that it does not meaningfully inhibit major CYP enzymes at therapeutic concentrations.

The real concern is pharmacodynamic convergence across three systems.

1. Cardiovascular and Blood Pressure

Bremelanotide raises blood pressure transiently with each dose. Testosterone, over time, may contribute to arterial stiffness and modestly raise blood pressure in women, particularly at supraphysiologic levels. A woman who already has a testosterone-related mild BP elevation is starting each bremelanotide dose from a higher baseline. The combined burden has not been formally studied, but the directional risk is additive. Women with any pre-existing hypertension should have stable BP control documented before combining these therapies.

2. Polycythemia and Hematocrit

Testosterone stimulates erythropoiesis. Even in women using female-appropriate doses, hematocrit can rise into ranges that increase blood viscosity and thrombotic risk. Bremelanotide, through MC receptor activation, has theoretical effects on melanocortin signaling pathways that interact with adrenal and pituitary axes, though direct erythropoietic effects are not established in the label. The combination means that any undetected erythrocytosis from testosterone will not be caught unless baseline CBC is checked before adding bremelanotide.

3. Lipid Profile

Testosterone therapy, especially oral formulations and high-dose pellets, lowers HDL cholesterol. A 2023 analysis in Menopause journal found that HDL reductions were most pronounced with oral methyltestosterone and supraphysiologic pellet doses. Bremelanotide's label does not list lipid changes as a primary adverse effect, but the cardiovascular risk burden from depressed HDL in the context of recurrent transient BP spikes from bremelanotide warrants a baseline lipid panel.

Life-Stage Considerations: Who Is Using Both and Why

HSDD exists across every reproductive life stage, but the hormonal context shifts substantially.

Reproductive Years (Premenopausal)

Bremelanotide is FDA-approved only for premenopausal women with acquired HSDD. Testosterone use in premenopausal women is off-label and less supported by the Global Consensus statement, which focuses its evidence base on postmenopausal populations. A premenopausal woman combining both agents is using one on-label drug alongside an off-label drug without a single trial examining their co-administration. This does not make the combination automatically wrong, but it should prompt a detailed risk-benefit conversation. Cycle phase can also affect baseline testosterone levels, and adding exogenous testosterone may disrupt ovulation, which carries significant implications for women who are not using contraception.

Perimenopause

Perimenopause is a high-traffic time for both medications. Desire often drops as estrogen fluctuates, and some clinicians prescribe testosterone to address this. Bremelanotide's approval does not extend to perimenopausal women, making any use in this stage technically off-label. Blood pressure variability is also more common in perimenopause, which raises concern about the transient BP spikes from bremelanotide.

Postmenopause

The Global Consensus statement most strongly endorses testosterone for HSDD in postmenopausal women. However, bremelanotide is not FDA-approved for this population. The RECONNECT trial enrolled only premenopausal women. Combining an off-label bremelanotide use with off-label testosterone in a postmenopausal woman creates a clinical situation where both the benefit data and the interaction data are extrapolated. The Menopause Society's 2022 hormone therapy position statement does not specifically address bremelanotide, but it emphasizes individualized cardiovascular risk assessment for any androgen therapy.

The following framework can help clinicians and patients structure the decision to combine these therapies:

The WomanRx HSDD Combination Assessment Framework

| Life Stage | Bremelanotide Status | Testosterone Status | Key Risk Layer | Minimum Monitoring | |---|---|---|---|---| | Premenopausal | On-label | Off-label | Ovulation disruption, BP | CBC, lipids, BP, free testosterone | | Perimenopausal | Off-label | Off-label | BP variability, erythrocytosis | CBC, lipids, BP, cardiovascular history | | Postmenopausal | Off-label | Off-label (Global Consensus supported) | Polycythemia, cardiovascular | CBC (q6 months), lipids (annual), BP each visit |

Pregnancy, Lactation, and Contraception: A Critical Section

Both drugs are contraindicated in pregnancy. This is not a nuance. It is a hard stop.

Bremelanotide in pregnancy: The FDA label states that bremelanotide caused fetal harm in animal studies at doses equivalent to human therapeutic exposure. There are no adequate human data. Bremelanotide should be discontinued if pregnancy is confirmed. Women of reproductive potential must use effective contraception while taking bremelanotide.

Testosterone in pregnancy: Testosterone is a Pregnancy Category X teratogen. Exposure during organogenesis causes virilization of a female fetus and genital malformations. Any woman using testosterone who could become pregnant must use reliable contraception. The Global Consensus statement explicitly recommends that testosterone not be prescribed to women planning pregnancy.

Lactation: Neither bremelanotide nor testosterone has been studied in human lactation in the formal pharmacokinetic sense. The FDA label for bremelanotide advises against use during breastfeeding due to unknown transfer into human milk. Testosterone transfers into breast milk, and LactMed recommends against its use during lactation because of potential effects on infant development. If you are breastfeeding, neither drug is appropriate.

Contraception requirements: If you are premenopausal and using either drug, use a non-hormonal or hormonal contraceptive method that you and your clinician agree does not interact with your testosterone dosing (combined oral contraceptives can raise SHBG and lower free testosterone, potentially blunting the therapy's effect). An intrauterine device or barrier method may be more appropriate in this specific clinical context.

What the Evidence Actually Shows (and Where It Does Not Exist)

Women have historically been underrepresented in clinical trials. The RECONNECT trials (phase 3) enrolled 1,247 women and showed bremelanotide increased satisfying sexual events by a mean of 0.5 per month versus placebo (a statistically significant but modest effect size), and improved the Female Sexual Function Index desire domain score by 0.3 points versus placebo. No trial has enrolled women on concurrent testosterone therapy. No randomized data exist on the combination.

For testosterone in women, the Intrinsa transdermal patch trial (ADORE) and the broader evidence reviewed in the Global Consensus statement showed that 300 mcg/day transdermal testosterone significantly increased satisfying sexual events in postmenopausal women by approximately 1.0 additional event per month versus placebo. This population was not on bremelanotide.

The honest answer to "is this combination safe and effective?" is: we do not know from direct data. What we can do is reason from mechanism, manage known individual risks, and monitor closely.

Drug Interaction Databases: What They Say

Standard clinical decision-support tools (Lexicomp, Micromedex, Clinical Pharmacology) do not currently list a high-severity pharmacokinetic interaction between bremelanotide and testosterone. This absence reflects limited data, not confirmed safety. The pharmacodynamic overlap is the clinical concern, not enzymatic competition. Clinicians relying solely on a "no interaction found" alert from an EMR-integrated tool may miss the physiologic risk stack described above.

PubMed searches as of January 2025 return no published trial or case series specifically examining co-administration of bremelanotide and testosterone in women. This is a genuine evidence gap.

Monitoring Protocol When Both Are Used

If a clinician determines that the combination is appropriate for a specific patient after individualized risk assessment, the following monitoring approach is reasonable based on guideline extrapolation from each drug's independent evidence base.

Before Starting

• Complete blood count with differential (baseline hematocrit)
• Fasting lipid panel
• Blood pressure (two readings, seated, 5 minutes apart)
• Serum testosterone by liquid chromatography-tandem mass spectrometry (LC-MS/MS), both total and free
• Confirm pregnancy is excluded and discuss contraception
• Review cardiovascular history (personal and family)

During Therapy

• Repeat CBC at 3 to 6 months after initiating or adjusting testosterone dose; annually if stable
• Repeat lipid panel at 6 to 12 months
• Blood pressure check at each visit; bremelanotide should not be used if systolic BP is consistently above 130 mmHg without stable antihypertensive management
• Monitor serum testosterone at 4 to 6 weeks after any dose change and then every 6 months
• If hematocrit rises above 52%, testosterone dose should be reduced or held; do not add bremelanotide until erythrocytosis is resolved

Dose Adjustment Considerations

Bremelanotide has a fixed approved dose of 1.75 mg per injection, so dose titration is not an option. If transient BP elevations are pronounced or cumulative cardiovascular risk increases, discontinuation of bremelanotide rather than dose reduction is the only pharmacologic lever. Testosterone, by contrast, can be titrated; lowering the dose to the minimum that maintains free testosterone in the physiologic female range reduces the erythrocytic and lipid risks.

Who This Approach Is Right For and Who It Is Not

Potentially Appropriate

A postmenopausal woman on low-dose transdermal testosterone (300 mcg/day patch equivalent or less) with stable serum testosterone in the physiologic range, normal hematocrit, a lipid panel without concerning HDL suppression, and controlled or no hypertension may be a candidate for a supervised trial of bremelanotide if testosterone alone has not fully addressed HSDD. She should be a non-smoker or former smoker without cardiovascular disease.

Likely Not Appropriate

• Any woman currently pregnant or not using reliable contraception
• Women with uncontrolled hypertension (systolic consistently above 130 mmHg)
• Women with hematocrit above 50% on testosterone therapy
• Women on testosterone pellets with supraphysiologic serum testosterone levels
• Women with a personal history of polycythemia vera or thromboembolic disease
• Women currently breastfeeding

Other Vyleesi Drug Interactions to Know

While testosterone is the focus here, bremelanotide has one particularly important pharmacokinetic interaction that affects women broadly: it delays gastric emptying. The FDA label specifically warns that bremelanotide can reduce the rate and extent of absorption of orally administered drugs that depend on gastric absorption. This means oral contraceptive pills, oral estradiol, oral progesterone, and any other time-sensitive oral medication taken near the time of a bremelanotide injection may be absorbed more slowly or in lower amounts. Women taking oral hormone therapy or oral contraceptives should take those medications at least one hour before their bremelanotide injection, or use a non-oral route where available.

Naltrexone and drugs affecting opioid receptors may have additive or opposing CNS effects with bremelanotide given its peptide receptor pharmacology, though this is not quantified in formal interaction studies. Alcohol and CNS depressants do not have a specific listed interaction but can compound the nausea that is bremelanotide's most common adverse effect, reported in 40% of women in the RECONNECT trial.

Counseling Points for Your Appointment

Here is what to tell your clinician before combining these therapies:

1. Bring your most recent testosterone lab result (specify the assay type; LC-MS/MS is preferred over immunoassay for accuracy in women).
2. Bring your most recent CBC, lipid panel, and blood pressure reading.
3. Tell your clinician exactly what testosterone formulation you use, the dose, and how often.
4. Confirm you are using effective contraception if you are premenopausal.
5. Ask your clinician to document baseline cardiovascular risk before the first bremelanotide injection.
6. Know the signs of polycythemia: headache, dizziness, ruddy skin, and fatigue that does not improve with rest. These warrant a CBC check before the next testosterone dose.

If your prescriber is not familiar with the Global Consensus Position Statement on Testosterone Therapy for Women, sharing that document can support an informed conversation.